Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer

Patients with triple-negative breast cancer (TNBC) who have residual disease after neoadjuvant therapy have a high risk of recurrence. We tested the impact of DNA-damaging chemotherapy alone or with PARP inhibition in this high-risk population. Patients with TNBC or deleterious BRCA mutation (TNBC/B...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalra, Maitri, Tong, Yan, Jones, David R., Walsh, Tom, Danso, Michael A., Ma, Cynthia X., Silverman, Paula, King, Mary-Claire, Badve, Sunil S., Perkins, Susan M., Miller, Kathy D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985189/
https://www.ncbi.nlm.nih.gov/pubmed/33753748
http://dx.doi.org/10.1038/s41523-021-00240-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985189/
https://www.ncbi.nlm.nih.gov/pubmed/33753748
http://dx.doi.org/10.1038/s41523-021-00240-w

Ejemplares similares